Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients

In this study, we examined the association between the pharmacokinetics (PK) level of sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in terms of adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). The PK of sunitinib (SU and DSU) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Numakura, Kazuyuki, Fujiyama, Nobuhiro, Takahashi, Makoto, Igarashi, Ryoma, Tsuruta, Hiroshi, Maeno, Atsushi, Huang, Mingguo, Saito, Mitsuru, Narita, Shintaro, Inoue, Takamitsu, Satoh, Shigeru, Tsuchiya, Norihiko, Niioka, Takenori, Miura, Masatomo, Habuchi, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982748/
https://www.ncbi.nlm.nih.gov/pubmed/29861870
http://dx.doi.org/10.18632/oncotarget.25423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982748/
https://www.ncbi.nlm.nih.gov/pubmed/29861870
http://dx.doi.org/10.18632/oncotarget.25423

Ejemplares similares